SMS Lifesciences India Gelecekteki Büyüme
Future kriter kontrolleri 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for SMS Lifesciences India.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
n/a
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 18.4% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | None |
Son güncelleme | n/a |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Improved Earnings Required Before SMS Lifesciences India Limited (NSE:SMSLIFE) Stock's 58% Jump Looks Justified
Aug 27Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Aug 01SMS Lifesciences India Limited (NSE:SMSLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Jun 13SMS Lifesciences India (NSE:SMSLIFE) Use Of Debt Could Be Considered Risky
Feb 10There's Reason For Concern Over SMS Lifesciences India Limited's (NSE:SMSLIFE) Massive 30% Price Jump
Jan 05Should Shareholders Reconsider SMS Lifesciences India Limited's (NSE:SMSLIFE) CEO Compensation Package?
Sep 23SMS Lifesciences India (NSE:SMSLIFE) Is Paying Out A Dividend Of ₹1.50
Sep 07SMS Lifesciences India (NSE:SMSLIFE) Has Affirmed Its Dividend Of ₹1.50
Aug 24SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 16SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 02SMS Lifesciences India (NSE:SMSLIFE) Takes On Some Risk With Its Use Of Debt
Jun 03With EPS Growth And More, SMS Lifesciences India (NSE:SMSLIFE) Is Interesting
May 13SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Nov 23Is Now The Time To Put SMS Lifesciences India (NSE:SMSLIFE) On Your Watchlist?
Jun 21Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Feb 22SMS Lifesciences India Limited's (NSE:SMSLIFE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 04Insider Buying: The SMS Lifesciences India Limited (NSE:SMSLIFE) MD & Executive Director Just Bought 19% More Shares
Nov 27Does SMS Lifesciences India (NSE:SMSLIFE) Have A Healthy Balance Sheet?
Nov 24Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak SMS Lifesciences India yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.
SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
6/30/2024 | 3,239 | 179 | N/A | N/A | N/A |
3/31/2024 | 3,060 | 91 | 34 | 243 | N/A |
12/31/2023 | 2,797 | 49 | N/A | N/A | N/A |
9/30/2023 | 3,121 | 46 | -176 | 120 | N/A |
6/30/2023 | 3,079 | 67 | N/A | N/A | N/A |
3/31/2023 | 3,156 | 115 | -339 | 147 | N/A |
12/31/2022 | 3,475 | 189 | N/A | N/A | N/A |
9/30/2022 | 3,505 | 172 | -624 | 6 | N/A |
6/30/2022 | 3,558 | 247 | N/A | N/A | N/A |
3/31/2022 | 3,501 | 253 | -624 | -112 | N/A |
12/31/2021 | 3,366 | 213 | N/A | N/A | N/A |
9/30/2021 | 3,118 | 216 | -82 | 364 | N/A |
6/30/2021 | 2,871 | 147 | N/A | N/A | N/A |
3/31/2021 | 2,656 | 136 | -4 | 352 | N/A |
12/31/2020 | 2,291 | 106 | N/A | N/A | N/A |
9/30/2020 | 2,091 | 76 | -163 | 61 | N/A |
6/30/2020 | 2,237 | 79 | N/A | N/A | N/A |
3/31/2020 | 2,608 | 102 | -88 | 145 | N/A |
12/31/2019 | 3,220 | 127 | N/A | N/A | N/A |
9/30/2019 | 3,970 | 188 | N/A | N/A | N/A |
6/30/2019 | 4,098 | 195 | N/A | N/A | N/A |
3/31/2019 | 3,779 | 178 | 56 | 300 | N/A |
12/31/2018 | 2,997 | 146 | N/A | N/A | N/A |
9/30/2018 | 2,697 | 119 | N/A | N/A | N/A |
6/30/2018 | 2,315 | 85 | N/A | N/A | N/A |
3/31/2018 | 2,130 | 65 | N/A | 80 | N/A |
12/31/2017 | 2,148 | 72 | N/A | N/A | N/A |
6/30/2017 | 2,034 | 90 | N/A | N/A | N/A |
3/31/2017 | 2,159 | 129 | N/A | 197 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if SMSLIFE's forecast earnings growth is above the savings rate (6.7%).
Kazançlar ve Piyasa: Insufficient data to determine if SMSLIFE's earnings are forecast to grow faster than the Indian market
Yüksek Büyüme Kazançları: Insufficient data to determine if SMSLIFE's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if SMSLIFE's revenue is forecast to grow faster than the Indian market.
Yüksek Büyüme Geliri: Insufficient data to determine if SMSLIFE's revenue is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if SMSLIFE's Return on Equity is forecast to be high in 3 years time